InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be represented at two upcoming investor events. The company announced that members of its executive team will be participating in the Tribe Public Webinar, slated for May 31, 2023, and the Investor Summit, scheduled for June 1, 2023. According to the announcement, InMed CEO Eric A. Adams and BayMedica VP of sales and marketing Jerry Griffin will cohost a presentation for the Tribe Public Webinar. The virtual presentation, titled “Addressing the Increasing Demand for Rare Cannabinoids,” will begin at 12 p.m. ET and will include time for questions and answers. At the Investor Summit, Adams will present a corporate overview followed by a Q&A session; his presentation is scheduled to begin at 11:30 a.m. ET. Both presentations will be available on the company’s website following the conclusion of the events.
To view the Tribe Public Webinar presentation, visit https://ibn.fm/64lq8
To view the Investor Summit presentation, visit https://ibn.fm/niORz
To view the full press release, visit https://ibn.fm/ZaY2x
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork